Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

1.64
+0.00500.31%
Post-market: 1.61-0.0250-1.53%19:30 EDT
Volume:622.64K
Turnover:1.02M
Market Cap:230.73M
PE:-3.57
High:1.67
Open:1.65
Low:1.62
Close:1.63
52wk High:3.10
52wk Low:1.33
Shares:141.12M
Float Shares:101.18M
Volume Ratio:0.76
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4578
EPS(LYR):-0.4702
ROE:-57.40%
ROA:-19.76%
PB:2.58
PE(LYR):-3.48

Loading ...

Proqr Therapeutics Nv - Files to Register Resale of up to 3.03 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS
·
Jul 07

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

TIPRANKS
·
Jul 06

Proqr Director Bart Filius Acquires 150,000 Shares for $231,000

Reuters
·
Jul 01

Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

TIPRANKS
·
Jun 29

Proqr Sells 5,100,780 Shares to Lilly in $9.2 Million Private Placement at $1.81 Each

Reuters
·
Jun 26

ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint

MT Newswires Live
·
Jun 25

ProQR Therapeutics prices 27.62M shares at $1.81 in registered direct offering

TIPRANKS
·
Jun 25

ProQR Therapeutics announces positive Phase 1 data for AX-0810

TIPRANKS
·
Jun 25

Proqr Prices $50 Million Follow-on Offering at $1.81 Per Share

Reuters
·
Jun 25

Proqr Therapeutics Nv - to Use Proceeds for Research, Clinical Development, and General Corporate Purposes

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Eli Lilly to Purchase 5.1 Mln Proqr Shares at $1.81/share for $9.2 Mln

THOMSON REUTERS
·
Jun 25

Proqr Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

THOMSON REUTERS
·
Jun 25

Proqr Reports Phase 1 Target Engagement for Ax-0810 RNA Editing Drug in Healthy Volunteers

Reuters
·
Jun 25

Proqr Therapeutics Nv - Phase 2 Program Expected to Start Mid-2027 with Interim Data by Mid-2028

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-810 Shows Favorable Safety Profile and Eight-week Half-life

THOMSON REUTERS
·
Jun 25

Proqr Announces Positive Phase 1 Target Engagement Data for Ax-0810, Establishing First Clinical Validation of the Axiomer Rna Editing Platform

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-422 Cta Filing for Mps1 Expected Early 2027 with Initial Data First Half 2027

THOMSON REUTERS
·
Jun 25

Proqr Therapeutics Nv - Ax-2911 First-in-human Iit in China Expected First Half 2027

THOMSON REUTERS
·
Jun 25

ProQR Therapeutics holds annual shareholder meeting, backs 2025 accounts 99.7%

Reuters
·
Jun 03

ProQR Therapeutics files Form 3 for director Hinsch Gylvin Lykke

Reuters
·
Jun 03